FDA Warning Letter Is Inadmissible Hearsay, Arkansas Supreme Court Says In Tossing J&J Judgment
This article was originally published in The Pink Sheet Daily
Executive Summary
Court throws out $1.2 billion award to the state of Arkansas over Risperdal promotions.
You may also be interested in...
J&J Risperdal Off-Label Settlement Includes Exec Pay Recoupment Provision
Janssen subsidiary pleads guilty as part of $2.2 billion deal that also requires audits of sales rep compensation.
Risperdal Marketing Settlement Prevents Reprint Distribution Without sNDA
J&J’s agreement with state AGs, which involves payments totaling $181 million, sets a number of restrictions on the company’s marketing practices for atypical antipsychotics that will be in effect for five years.
J&J Says Penalties In Arkansas Risperdal Case ‘Excessive,’ Seeks New Trial
Argues that Arkansas Medicaid spent less than $10 million on Risperdal, but the fine imposed by a state judge for deceptive marketing practices would exceed $1.2 billion.